P088. Is patient reported outcome (PRO) affected by different follow-up regimes in inflammatory bowel disease (IBD)? A one year prospective, longitudinal comparison of nurse-led versus conventional follow-up
L.‑P. Jelsness-Jørgensen1, T. Bernklev2, M. Henriksen1, R. Torp3, B. Moum4
1Østfold Hospital Trust, Norway; 2Telemark Hospital Trust, Norway; 3Innlandet Hospital Trust, Norway; 4Oslo University Hospital, Department of Gastroenterology, Oslo, Norway
Background: Specialist nurses have become increasingly involved in the management of Inflammatory Bowel Disease (IBD). The effect of such involvement on patient reported outcomes has however, been scarcely studied. The objectives of this study were consequently to investigate the impact of nurse-led versus conventional follow-up on patient outcomes, such as e.g., fatigue, quality of life, worries and time from relapse to start of treatment.
Methods: Patients completed the Fatigue questionnaire (FQ), the Short Form 36 (SF-36), Inflammatory Bowel Disease Questionnaire (N-IBDQ) and the Rating Form of IBD Patient Concerns (RFIPC) at baseline and after one year. Socio-demographic and clinical variables were obtained at V1 and V3. In addition the amount of e.g., relapses, hospitalisations, surgery, time from relapse to start of treatment and sick-leave were recorded during the follow-up period.
Results: A total of 140 patients were included; ulcerative colitis (UC) n = 92, Crohn's disease (CD) n = 48, mean age 46.9 and 40.0 years old, respectively. One hundred and thirty tree patients attended the follow-up after one year. After one year there were no differences between the groups in relation to fatigue, quality of life, worries, amount of relapse, sick-leave, hospitalisations or surgery. Participants in nurse-led follow-up had a significantly (P < 0.05) shorter interval from the start of a relapse to the start of treatment.
Conclusions: Nurse-led follow-up of IBD patients produces PRO results comparable to that of gastroenterologists and may shorten the interval from the beginning of a relapse to the start of treatment.